Drugs that contain Cariprazine Hydrochloride
1. Drug name - VRAYLAR
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7943621 | ALLERGAN | Salts of piperazine compounds as D3/D2 antagonists |
Dec, 2028
(6 years from now) | |
| US7737142 | ALLERGAN | (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists |
Sep, 2029
(6 years from now) | |
| CN1829703B | ALLERGAN | As A D 3 /D 2 Receptor Antagonist (Thio) Carbamoyl-Cyclohexane Derivatives |
May, 2024
(1 year, 7 months from now) | |
| CN1829703A | ALLERGAN | As D |
May, 2024
(1 year, 7 months from now) | |
| CN101679315A | ALLERGAN | Novel Piperazine Salts As D3/D2 Antagonists |
May, 2028
(5 years from now) | |
| CN101679315B | ALLERGAN | A D <Sub> 3 </Sub> /D <Sub> 2 </Sub> A Piperazine Salt. |
May, 2028
(5 years from now) | |
| IN200904256P2 | ALLERGAN | Novel Piperazine Salts As D3/D2 Antagonists |
May, 2028
(5 years from now) | |
| IN293352B | ALLERGAN | A Process For The Preparation Of Novel Piperazine Salts As D3/D2 Antagonists |
May, 2028
(5 years from now) | |
| EP1663996A1 | ALLERGAN | (Thio)Carbamoyl-Cyclohexane Derivatives As D3/D2 Receptor Antagonists |
May, 2024
(1 year, 7 months from now) | |
| EP1663996B1 | ALLERGAN | (Thio)Carbamoyl-Cyclohexane Derivatives As D3/D2 Receptor Antagonists |
May, 2024
(1 year, 7 months from now) | |
| EP2155696A2 | ALLERGAN | Piperazine Salts As D3/D2 Antagonists |
May, 2028
(5 years from now) | |
| EP2155696B1 | ALLERGAN | Piperazine Salts As D3/D2 Antagonists |
May, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE47350 | ALLERGAN | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(6 years from now) | |
Treatment: Treatment of schizophrenia and/or acute manic or mixed episodes associated with bipolar i disorder with cariprazine; treatment of schizophrenia with cariprazine; treatment of acute manic or mixed episodes associated with bipolar i disorder with cariprazine; treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazine
Dosage: CAPSULE;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 1.5MG BASE | CAPSULE;ORAL | Prescription |
| EQ 3MG BASE | CAPSULE;ORAL | Prescription |
| EQ 4.5MG BASE | CAPSULE;ORAL | Prescription |
| EQ 6MG BASE | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.